IRIDEX Corporation (Nasdaq: IRIX), a leader in laser-based medical systems, announced its financial results for the fourth quarter and full year ended January 3, 2026. The company reported total revenue of $14.7 million for Q4 2025, marking a 16% increase from $12.7 million in the same quarter of the previous year. This growth was driven by strong sales in its retina and glaucoma product lines, particularly the Cyclo G6 product family, which generated $3.8 million in revenue, up 15% year-over-year. The company sold 15,900 Cyclo G6 probes, an increase from 13,300 in the prior year quarter. Additionally, IRIDEX reported a net loss of $0.2 million, or $0.01 per share, compared to a net loss of $0.8 million, or $0.05 per share, in Q4 2024. For the full year, IRIDEX generated total revenue of $52.7 million, an 8% increase from $48.7 million in 2024. The company also achieved a significant reduction in operating expenses, down 22% to $21.8 million, contributing to an improved adjusted EBITDA of $1.1 million. Looking ahead, IRIDEX forecasts 2026 revenue between $51 million and $53 million, despite potential market disruptions from geopolitical conflicts. The company remains optimistic about its operational efficiencies and growth prospects in the coming year.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.